Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide with broad anti-inflammatory, immunomodulatory, and neuroprotective properties. First identified in the gut (where it regulates motility, secretion, and blood flow), VIP is now recognized as a pleiotropic signaling molecule with receptors distributed throughout virtually every organ system — including the lungs, brain, immune cells, gastrointestinal tract, and cardiovascular system.

VIP acts through two G-protein-coupled receptors: VPAC1 (widely distributed, particularly on immune cells and epithelial surfaces) and VPAC2 (concentrated in the central nervous system, smooth muscle, and specific immune cell subsets). This broad receptor distribution explains VIP's wide-ranging effects and its relevance to systemic inflammatory conditions.

VIP has received the most clinical attention in the context of Chronic Inflammatory Response Syndrome (CIRS), where Dr. Ritchie Shoemaker's treatment protocol positions VIP as the final step in a sequential approach to resolving biotoxin-induced systemic inflammation. This protocol covers both the CIRS-specific application and broader anti-inflammatory use cases.

Dose selection

Intranasal route (primary for CIRS and neuroinflammation):

Standard dose: 50 mcg per nostril (100 mcg total) per administration
Starting dose: 25 mcg per nostril for the first 3-5 days to assess tolerability
Frequency: 2-4 times daily, depending on symptom severity and response

Subcutaneous route (systemic inflammation):

Standard dose: 50-100 mcg per injection
Starting dose: 25-50 mcg for initial assessment
Frequency: 1-2 times daily

Route selection rationale: Intranasal administration delivers VIP directly to the nasal mucosa and, via the olfactory pathway, provides partial direct CNS access. This is the preferred route for conditions with a significant neuroinflammatory component — CIRS-related cognitive symptoms, mast cell activation affecting the upper airway, and neuroinflammatory conditions. Subcutaneous administration provides more reliable systemic bioavailability and is preferred when the primary target is peripheral inflammation — gut inflammation, systemic cytokine elevation, or autoimmune-related tissue inflammation.

Some practitioners use both routes simultaneously in severe cases — intranasal for CNS targeting and subcutaneous for systemic coverage. This combined approach requires careful dose management and monitoring.

Timing and administration

Intranasal administration:

Prepare the VIP nasal spray by reconstituting lyophilized VIP with bacteriostatic water to the desired concentration (typically calibrated so that one spray delivers 25-50 mcg). Administer using the same technique as other intranasal peptides — head tilted slightly forward, gentle inhalation during spray delivery, nozzle angled toward the outer nasal wall. Avoid forceful sniffing that pulls the solution past the olfactory epithelium.

Timing: Space doses evenly throughout the day. For twice-daily dosing, morning and evening. For four-times-daily dosing, upon waking, midday, late afternoon, and evening. VIP has a relatively short half-life (approximately 1-2 minutes in plasma, though tissue effects persist longer), making multiple daily administrations important for maintaining therapeutic coverage.

Subcutaneous administration: Standard subcutaneous injection technique. Abdomen or upper thigh preferred. No specific fasting requirements — VIP's mechanism is not affected by gastrointestinal contents when administered parenterally.

Important Shoemaker protocol context: In the CIRS treatment sequence, VIP is not used until earlier steps have been completed — cholestyramine or Welchol binding therapy, correction of MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) nasal colonization, correction of antigliadin antibodies, and normalization of other biomarkers. Initiating VIP before these prerequisites are met can result in inadequate response or paradoxical symptom exacerbation, because VIP cannot overcome ongoing biotoxin exposure or active nasal biofilm infection. The sequential approach matters.

Cycle structure

CIRS protocol: VIP is typically administered continuously (not cycled) for 1-3 months as part of the Shoemaker treatment sequence. The endpoint is normalization of specific biomarkers (VIP levels, TGF-beta-1, C4a, MSH) rather than an arbitrary time duration. Once biomarkers normalize and symptoms resolve, VIP is tapered and discontinued.

Non-CIRS anti-inflammatory use: 4-8 weeks on, 2-4 weeks off. The active phase should be long enough to assess biomarker response (minimum 4 weeks for blood markers to show meaningful trends). The off-period allows assessment of whether anti-inflammatory benefits persist (suggesting the underlying inflammatory driver has been addressed) or recur (suggesting ongoing VIP support or investigation of persistent inflammatory triggers is needed).

Chronic use considerations: Some CIRS patients require extended or recurring VIP therapy due to ongoing environmental exposures or incomplete resolution of upstream triggers. In these cases, VIP may be used for 3-6 months continuously with regular biomarker monitoring. This should be physician-supervised, with periodic reassessment of whether the underlying causes have been adequately addressed.

Monitoring

Monitoring is essential for VIP therapy, particularly in the CIRS context where specific biomarker targets guide treatment decisions.

Core inflammatory panel:

TGF-beta-1: Elevated in CIRS and many chronic inflammatory conditions. Should trend downward with effective VIP therapy. Target: normalization to laboratory reference range.
C4a: A complement activation fragment elevated in CIRS. Tracks with disease activity and should decrease with treatment. An important marker of innate immune activation.
MSH (alpha-melanocyte stimulating hormone): Typically low in CIRS patients. VIP therapy, along with resolution of upstream triggers, should support MSH recovery. MSH is itself an anti-inflammatory peptide, so its recovery indicates restoration of endogenous anti-inflammatory signaling.
VIP levels (serum): Paradoxically, many CIRS patients have low endogenous VIP levels. Exogenous VIP therapy should normalize circulating levels. If VIP levels do not rise despite supplementation, absorption or compliance issues should be investigated.

Broader inflammatory markers:

hs-CRP (systemic inflammation)
IL-6, TNF-alpha, IL-1 beta (pro-inflammatory cytokines)
MMP-9 (matrix metalloproteinase-9, elevated in CIRS and reflects vascular inflammation)
VEGF (vascular endothelial growth factor, often dysregulated in CIRS)

Pulmonary monitoring: VIP plays a significant role in pulmonary regulation — it relaxes bronchial smooth muscle, reduces pulmonary artery pressure, and modulates pulmonary immune responses. In individuals with pulmonary involvement (chronic cough, exercise-induced dyspnea, or pulmonary hypertension), pulmonary function tests and/or echocardiography at baseline and follow-up provide objective assessment.

Gastrointestinal assessment: VIP is a major regulator of gut motility and intestinal barrier function. Improvements in digestive symptoms, stool consistency, and potentially markers of intestinal permeability (zonulin, lactulose-mannitol test) may reflect VIP's gut-protective effects.

Common combinations

VIP + BPC-157 (250-500 mcg subcutaneously, 1-2 times daily): BPC-157 is a gastric pentadecapeptide with tissue-healing and anti-inflammatory properties. While VIP addresses systemic immune dysregulation through receptor-mediated immunomodulation, BPC-157 promotes tissue repair at sites of damage — gut mucosa, connective tissue, and vasculature. This combination is particularly relevant for individuals with both systemic inflammation and localized tissue injury (e.g., CIRS patients with concurrent gut barrier dysfunction or injury).

VIP + KPV (100-500 mcg, oral or subcutaneous): KPV is a tripeptide fragment of alpha-MSH (the same MSH that is depleted in CIRS). KPV acts through melanocortin receptors to suppress NF-kB-mediated inflammation, complementing VIP's VPAC-receptor-mediated anti-inflammatory effects. This combination provides anti-inflammatory coverage through two independent receptor systems and may be particularly useful in cases where MSH levels remain low despite other interventions.

VIP + Low-Dose Naltrexone (LDN, 1.5-4.5 mg oral, nightly): LDN modulates immune function through transient opioid receptor blockade, which upregulates endorphin production and modulates Toll-like receptor signaling on immune cells. While not a peptide, LDN is commonly combined with VIP in CIRS protocols and addresses the immune dysregulation component from a different mechanistic angle.

VIP + Cholestyramine or Welchol (as per Shoemaker protocol): In the CIRS context, VIP is used alongside binding agents that remove biotoxins from enterohepatic circulation. This is not optional — it is a prerequisite for VIP effectiveness in CIRS.

Contraindications and cautions

Hypotension: VIP is a vasodilator. Individuals with baseline low blood pressure or those taking antihypertensive medications should use VIP cautiously, starting at the lowest dose and monitoring blood pressure. Symptoms of VIP-induced vasodilation include flushing, lightheadedness, and nasal congestion.

Active diarrhea: VIP stimulates intestinal secretion and motility at higher concentrations. In individuals with active diarrhea (regardless of cause), VIP may worsen symptoms. Address the diarrhea before initiating VIP, or start at the lowest dose with careful monitoring.

VIPoma history: VIPomas are rare neuroendocrine tumors that secrete excessive VIP, causing watery diarrhea, hypokalemia, and achlorhydria (WDHA syndrome). While this is an extremely rare condition, any history of VIPoma is an absolute contraindication.

Active MARCoNS infection: In the CIRS context, initiating VIP before resolving MARCoNS nasal colonization can worsen outcomes. MARCoNS produces biofilms and exotoxins that cleave MSH and interfere with the neuroimmune signaling that VIP supports. Treat MARCoNS first, confirm eradication with deep nasal culture, then initiate VIP.

Pregnancy and breastfeeding: Insufficient safety data for exogenous VIP administration during pregnancy or lactation.

Expected timeline

Days 1-7: VIP's vasodilatory effects may be noticeable within hours of first administration — mild nasal congestion (intranasal route), flushing, or warmth. These are pharmacological effects, not therapeutic outcomes, and typically diminish with continued use as the body acclimates.

Weeks 1-3: Early symptomatic improvements may emerge — reduced brain fog (a hallmark of CIRS), improved respiratory comfort, decreased generalized aching, and improved energy. These effects are variable and dose-dependent.

Weeks 3-8: Biomarker changes should become measurable. TGF-beta-1, C4a, and other inflammatory markers should trend toward normalization. MSH levels may begin to recover. Symptomatic improvements should solidify and become clearly distinguishable from baseline.

Months 2-3 (CIRS protocol): If earlier Shoemaker protocol steps were completed successfully, VIP therapy during this period should approach biomarker normalization. The treatment goal is resolution to the point where VIP can be tapered and discontinued, with the underlying inflammatory cascade broken. If biomarkers do not improve, reassess whether upstream triggers (ongoing mold exposure, persistent MARCoNS, unresolved biotoxin burden) are undermining VIP effectiveness.